Experimental brain diabetes produced by intracerebral administration of streptozotocin (STZ) shares many features with AD and is treatable with insulin sensitizer agents, that is, drugs currently used to treat type 2 diabetes mellitus (T2DM) [54]. This evidence concerns the gene INS and type 2 diabetes mellitus.